Recent Updates
Recently added Catalysts
KPTI Positive Sentiment Score: 70/100

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, October 1, 2025 1 min read
Key Takeaway: Karyopharm Therapeutics Inc. has granted 333 restricted stock units (RSUs) to a newly-hired employee as part of its efforts to incentivize talent under Nasdaq Listing Rule 5635(c)(4). This grant, effective as of September 30, 2025, will vest over three years, with a third of the shares vesting on each anniversary of the grant date. This initiative highlights Karyopharm's commitment to building its workforce as it continues to pioneer novel cancer therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Karyopharm Therapeutics is expanding its team with new hires.
  • The RSU grant is a strategic move to attract talent.
  • Vesting over three years indicates long-term commitment to new employees.

Full Press Release Details

NEWTON, Mass., Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
About Karyopharm Therapeutics
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.

21 %

more press release views with

Frequently Asked Questions

What is Karyopharm Therapeutics known for?

Karyopharm Therapeutics develops innovative cancer therapies.

How many RSUs were granted to the new employee?

The company granted 333 restricted stock units to a new employee.

When was the RSU award granted?

The RSU award was granted on September 30, 2025.

How will the RSUs vest over time?

The RSUs will vest over three years with annual 33 1/3% increments.

What is required for RSUs to vest?

Vesting is contingent on the employee's continued service at Karyopharm.

Tags: KPTI Viatris Investor Conferences Healthcare Karyopharm inducement grants Nasdaq stock units
Last updated: Oct 1, 2025